The FTC is attacking drugmakers’ ‘patent thickets’

0 minutes, 12 seconds Read




The Federal Trade Commission has challenged the validity of more than 100 drug product patents, focusing on devices used to deliver drugs such as inhalers and autoinjectors in an effort to increase competition and potentially lower some prices.



Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *